Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK. Zhang A, et al. Among authors: de sarkar n. Cancer Res Commun. 2023 Nov 20;3(11):2358-2374. doi: 10.1158/2767-9764.CRC-23-0250. Cancer Res Commun. 2023. PMID: 37823778 Free PMC article.
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. DeLucia DC, et al. Among authors: de sarkar n. Clin Cancer Res. 2021 Feb 1;27(3):759-774. doi: 10.1158/1078-0432.CCR-20-3396. Epub 2020 Nov 16. Clin Cancer Res. 2021. PMID: 33199493 Free PMC article.
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS. Kumar A, et al. Nat Med. 2016 Apr;22(4):369-78. doi: 10.1038/nm.4053. Epub 2016 Feb 29. Nat Med. 2016. PMID: 26928463 Free PMC article.
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML. Baca SC, et al. Among authors: de sarkar n. Nat Commun. 2021 Mar 30;12(1):1979. doi: 10.1038/s41467-021-22139-7. Nat Commun. 2021. PMID: 33785741 Free PMC article.
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G. De Sarkar N, et al. Cancer Discov. 2023 Mar 1;13(3):632-653. doi: 10.1158/2159-8290.CD-22-0692. Cancer Discov. 2023. PMID: 36399432 Free PMC article.
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Nyquist MD, et al. Among authors: de sarkar n. Cell Rep. 2020 May 26;31(8):107669. doi: 10.1016/j.celrep.2020.107669. Cell Rep. 2020. PMID: 32460015 Free PMC article.
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. Among authors: de sarkar n. J Clin Invest. 2021 May 17;131(10):e146777. doi: 10.1172/JCI146777. J Clin Invest. 2021. PMID: 33998604 Free PMC article.
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS. De Sarkar N, et al. JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789. JCI Insight. 2021. PMID: 34877933 Free PMC article.
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY. Schweizer MT, et al. Among authors: de sarkar n. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):194-200. doi: 10.1038/s41391-022-00636-0. Epub 2022 Dec 23. Prostate Cancer Prostatic Dis. 2023. PMID: 36564459 Free PMC article.
33 results